Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Long term efficacy and safety of SARS-CoV-2 vaccination in Dutch patients with chronic kidney disease stage G4-G5, on dialysis or after kidney transplantation

    Summary
    EudraCT number
    2021-001520-18
    Trial protocol
    NL  
    Global end of trial date
    18 Dec 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    30 May 2024
    First version publication date
    30 May 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    NL76839.042.21
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04841785
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    UMCG
    Sponsor organisation address
    Hanzeplein 1, Groningen, Netherlands, 9713 GZ
    Public contact
    study coordinator, RECOVAC consortium, 0031 0503616161, a.l.messchendorp@umcg.nl
    Scientific contact
    study coordinator, RECOVAC consortium, 0031 0503616161, a.l.messchendorp@umcg.nl
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    19 Apr 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    18 Dec 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the efficacy of SARS-CoV vaccination by the incidence of COVID-19 in patients with chronic kidney disease stage G4-G5, on dialysis and patients after kidney transplantation who received SARS-CoV-2 vaccination
    Protection of trial subjects
    This study investigates the effect of registered vaccines that are administered in the context of routine clinical care. Therefore there are no potential issues of concern for the investigated medicinal products of this study and no extra protection of trial subjects is implemented The vaccinations will be administered according to the instructions of the manufacturers and to the most recent COVID-19 vaccination guideline for standard care provided by the Dutch National Institute for Public Health and the Environment (RIVM).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    22 Mar 2021
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety, Efficacy, Scientific research
    Long term follow-up duration
    2 Years
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Netherlands: 4868
    Worldwide total number of subjects
    4868
    EEA total number of subjects
    4868
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    2755
    From 65 to 84 years
    2096
    85 years and over
    17

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Possible eligible participants were all prioritized for primary COVID-19 vaccination and vaccinated via participating hospitals. They were invited to receive a study PIF by a flyer which was handed during the second vaccination. The were asked to preferably go to a survey, where an electronic version of the PIF could be found and ICF signed.

    Pre-assignment
    Screening details
    Via this way, 1200 kidney transplant recipients, 6000 dialysis patients and 6000 patients with CKD stage 4/5 were approached.

    Pre-assignment period milestones
    Number of subjects started
    4868
    Number of subjects completed
    4868

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    COVID-19 vaccination
    Arm description
    All patients entered in this study received a COVID-19 vaccination via the national vaccination programme of the Netherlands. Available vaccines were: 1. COVID-19 Vaccine Moderna 2. Comirnaty/ COVID-19 mRNA vaccine BioNTech/Pfizer 3. COVID-19 Vaccine AstraZeneca 4. COVID-19 Vaccine Janssen
    Arm type
    Experimental

    Investigational medicinal product name
    COVID-19 Vaccine Moderna
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    One dose (0.5 mL) contains 100 micrograms of messenger RNA (mRNA) (embedded in SM-102 lipid nanoparticles). COVID-19 Vaccine Moderna is administered as a course of 2 doses (0.5 mL each). It is recommended to administer the second dose 28 days after the first dose

    Investigational medicinal product name
    Comirnaty/ COVID-19 mRNA vaccine BioNTech/Pfizer
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose (0.3 mL) contains 30 micrograms of COVID-19 mRNA Vaccine (embedded in lipid nanoparticles). Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each) at least 21 days apart (

    Investigational medicinal product name
    COVID-19 Vaccine AstraZeneca
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    One dose (0.5 ml) contains: Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)*, not less than 2.5 × 108 infectious units (Inf.U). The COVID-19 Vaccine AstraZeneca vaccination course consists of two separate doses of 0.5 ml each. The second dose should be administered between 4 and 12 weeks (28 to 84 days) after the first dose

    Investigational medicinal product name
    COVID-19 Vaccine Janssen
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    One dose (0.5 mL) contains: Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein* (Ad26.COV2-S), not less than 8.92 log10 infectious units (Inf.U). Individuals 18 years of age and older COVID-19 Vaccine Janssen is administered as a single-dose of 0.5 mL by intramuscular injection only.

    Number of subjects in period 1
    COVID-19 vaccination
    Started
    4868
    Completed
    2862
    Not completed
    2006
         Adverse event, serious fatal
    278
         Consent withdrawn by subject
    56
         Deteriorating health
    5
         Lost to follow-up
    1656
         Protocol deviation
    11

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial (overall period)
    Reporting group description
    -

    Reporting group values
    Overall trial (overall period) Total
    Number of subjects
    4868 4868
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    2755 2755
        From 65-84 years
    2096 2096
        85 years and over
    17 17
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    60.0 ( 13.6 ) -
    Gender categorical
    Units: Subjects
        Female
    1963 1963
        Male
    2905 2905
    Subject analysis sets

    Subject analysis set title
    CKD G4/5
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Patients with chronic kidney disease stage G4/5

    Subject analysis set title
    Dialysis
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Subjects on dialysis (either hemodialysis or peritoneal dialysis)

    Subject analysis set title
    Kidney Transplant Recipients
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Patients that have a functioning kidney transplant

    Subject analysis sets values
    CKD G4/5 Dialysis Kidney Transplant Recipients
    Number of subjects
    393
    945
    3530
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    104
    373
    2278
        From 65-84 years
    289
    557
    1250
        85 years and over
    0
    15
    2
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    67.4 ( 12.2 )
    65.3 ( 12.6 )
    57.8 ( 13.3 )
    Gender categorical
    Units: Subjects
        Female
    159
    363
    2089
        Male
    234
    582
    1441

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    COVID-19 vaccination
    Reporting group description
    All patients entered in this study received a COVID-19 vaccination via the national vaccination programme of the Netherlands. Available vaccines were: 1. COVID-19 Vaccine Moderna 2. Comirnaty/ COVID-19 mRNA vaccine BioNTech/Pfizer 3. COVID-19 Vaccine AstraZeneca 4. COVID-19 Vaccine Janssen

    Subject analysis set title
    CKD G4/5
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Patients with chronic kidney disease stage G4/5

    Subject analysis set title
    Dialysis
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Subjects on dialysis (either hemodialysis or peritoneal dialysis)

    Subject analysis set title
    Kidney Transplant Recipients
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Patients that have a functioning kidney transplant

    Primary: Incidence of COVID-19 in a two years period after SARS-CoV-2 vaccination

    Close Top of page
    End point title
    Incidence of COVID-19 in a two years period after SARS-CoV-2 vaccination [1]
    End point description
    During the trial, the COVID-19 pandemic emerged, for which we were forced to adapt our endpoints somewhat. We have chosen to only report on COVID-19 after two vaccinations and before the third COVID-19 vaccination. There were too few patients in the CKD G4/5 group and Dialysis group to report on this endpoint.
    End point type
    Primary
    End point timeframe
    Within two years after vaccination
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As this is not a traditional study including comparisons between certain treatment groups, the statistical analysis that was applied for this specific endpoint could not be entered in EudraCT. For details on this analysis we would like to refer to a publication which can be found under 'More Information' PMID 38257814
    End point values
    Kidney Transplant Recipients
    Number of subjects analysed
    2885
    Units: subjects
    62
    No statistical analyses for this end point

    Secondary: The antibody response against the SARS-CoV-2 Receptor Binding Domain at 28 days after the 2nd COVID-19 vaccination.

    Close Top of page
    End point title
    The antibody response against the SARS-CoV-2 Receptor Binding Domain at 28 days after the 2nd COVID-19 vaccination.
    End point description
    End point type
    Secondary
    End point timeframe
    28 days after second COVID-19 vaccination
    End point values
    CKD G4/5 Dialysis Kidney Transplant Recipients
    Number of subjects analysed
    393
    480
    2468
    Units: BAU/mL
        median (inter-quartile range (Q1-Q3))
    2097 (828 to 4077)
    1375 (431 to 2896)
    65.7 (8.25 to 573.1)
    No statistical analyses for this end point

    Secondary: The antibody response against the SARS-CoV-2 Receptor Binding Domain at 28 days after the 3rd COVID-19 vaccination

    Close Top of page
    End point title
    The antibody response against the SARS-CoV-2 Receptor Binding Domain at 28 days after the 3rd COVID-19 vaccination
    End point description
    End point type
    Secondary
    End point timeframe
    28 days after third COVID-19 vaccination
    End point values
    CKD G4/5 Dialysis Kidney Transplant Recipients
    Number of subjects analysed
    40
    242
    1547
    Units: BAU/mL
        median (inter-quartile range (Q1-Q3))
    1551 (459 to 3225)
    1727 (570 to 4254)
    318.4 (35.0 to 1146)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information [1]
    Timeframe for reporting adverse events
    7 days after each COVID-19 vaccination
    Adverse event reporting additional description
    AEs were categorized in local AEs (pain or erythema at injection site and myalgia) or systemic AEs (fever, arthralgia, fatigue, headache and other).
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    Pre-defined
    Dictionary version
    1
    Frequency threshold for reporting non-serious adverse events: 0%
    Notes
    [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
    Justification: AEs are reported according to patient group (CKD G4/5, Dialysis, Kidney Transplant Recipients) and whitin these groups according to vaccine type and vaccine number in the publication that can be found under 'More Information' with PMID number: 36865021. The EudraCT results template is not suitable to provide the specific numbers this way.

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Nov 2021
    1. The time range that blood can be collected after second COVID-19 vaccination is extended to 28 -14/+28 days after vaccination 2. Addition of a questionnaire about general patient characteristics 3. Addition of a questionnaire about behavoural changes with regard to preventive measures during the pandemic 4. With the addition of a third vaccination we have changed the protocol for collection of a blood sample after 6 months for those who received a third vaccination to collection of a blood sample 28 days after receiving a third vaccination

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/36245996
    http://www.ncbi.nlm.nih.gov/pubmed/35123437
    http://www.ncbi.nlm.nih.gov/pubmed/36789469
    http://www.ncbi.nlm.nih.gov/pubmed/36865021
    http://www.ncbi.nlm.nih.gov/pubmed/37533418
    http://www.ncbi.nlm.nih.gov/pubmed/38428480
    http://www.ncbi.nlm.nih.gov/pubmed/38257814
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 11:05:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA